By Josh Beckerman
Alcon reported higher sales and earnings for the third quarter and lowered full-year sales guidance.
Shares were recently down 6.6% to $86.23 Tuesday.
Alcon, whose products include contact lenses and eye drops, said sales were helped by factors including product innovation, such as toric and multifocal lenses. Operating margin increased 0.9 percentage points amid improved operating leverage in selling, general and administrative expenses.
Net sales rose to $2.43 billion from $2.3 billion. Core earnings per share increased to 81 cents from 66 cents.
Alcon expects 2024 sales of $9.8 billion to $9.9 billion, compared with prior guidance of $9.9 billion to $10.1 billion. It expects core earnings per share of $3 to $3.05, compared with a previous outlook of $3 to $3.10.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 12, 2024 13:33 ET (18:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。